PDCD1 and neoplasm: These effects of Tislelizumab can be attributed to its activity as a monoclonal antibody that binds to PD-1 with high affinity and specificity and inhibits the binding of PD-1 to PD-L1, thus preventing T cell apoptosis, stimulating their cytokine activity, improving immune function and ultimately, inhibiting tumor cell growth.13,22–24